These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 10718103

  • 1. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA, Lamb HM.
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [Abstract] [Full Text] [Related]

  • 2. Moxifloxacin.
    Balfour JA, Wiseman LR.
    Drugs; 1999 Mar; 57(3):363-73; discussion 374. PubMed ID: 10193688
    [Abstract] [Full Text] [Related]

  • 3. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH.
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [Abstract] [Full Text] [Related]

  • 4. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA.
    Clin Infect Dis; 2001 Mar 15; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [Abstract] [Full Text] [Related]

  • 5. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM, Ormrod D, Hurst M, Onrust SV.
    Drugs; 2002 Mar 15; 62(1):169-207. PubMed ID: 11790160
    [Abstract] [Full Text] [Related]

  • 6. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ.
    Drugs; 2002 Mar 15; 62(1):13-59. PubMed ID: 11790155
    [Abstract] [Full Text] [Related]

  • 7. Moxifloxacin: clinical efficacy and safety.
    Culley CM, Lacy MK, Klutman N, Edwards B.
    Am J Health Syst Pharm; 2001 Mar 01; 58(5):379-88. PubMed ID: 11258173
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T, Pearl J, Williams J, Haverstock D, Church D.
    Respir Med; 2000 Feb 01; 94(2):97-105. PubMed ID: 10714413
    [Abstract] [Full Text] [Related]

  • 9. Moxifloxacin in respiratory tract infections.
    Miravitlles M.
    Expert Opin Pharmacother; 2005 Feb 01; 6(2):283-93. PubMed ID: 15757424
    [Abstract] [Full Text] [Related]

  • 10. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M, Anzueto A.
    Expert Opin Pharmacother; 2008 Jul 01; 9(10):1755-72. PubMed ID: 18570608
    [Abstract] [Full Text] [Related]

  • 11. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S, Decramer M.
    Expert Opin Pharmacother; 2008 Jul 01; 9(10):1735-44. PubMed ID: 18570606
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF, Goa KL.
    Drugs; 2003 Jul 01; 63(24):2769-802. PubMed ID: 14664657
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.
    Zhanel GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, Gin AS, Rubinstein E, Hoban DJ.
    Treat Respir Med; 2006 Jul 01; 5(6):437-65. PubMed ID: 17154673
    [Abstract] [Full Text] [Related]

  • 16. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
    Ball P.
    Int J Clin Pract; 2000 Jun 01; 54(5):329-32. PubMed ID: 10954961
    [Abstract] [Full Text] [Related]

  • 17. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ, Jung R, Garvin CG.
    Drug Saf; 2001 Jun 01; 24(3):199-222. PubMed ID: 11347723
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
    Hoeffken G, Meyer HP, Winter J, Verhoef L, CAP1 Study Group.
    Respir Med; 2001 Jul 01; 95(7):553-64. PubMed ID: 11453311
    [Abstract] [Full Text] [Related]

  • 20. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD, Lamb HM.
    Drugs; 1998 Sep 01; 56(3):487-515. PubMed ID: 9777318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.